Compare YDDL & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | AKBA |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.9M | 343.4M |
| IPO Year | 2024 | 2014 |
| Metric | YDDL | AKBA |
|---|---|---|
| Price | $1.75 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 10.0K | ★ 3.9M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $0.82 |
| 52 Week High | $16.23 | $3.32 |
| Indicator | YDDL | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | N/A |
| Support Level | $1.65 | N/A |
| Resistance Level | $1.93 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 44.44 | 0.00 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.